Article Versions Notes

Khanna S, Sims M, Louie TJ, Fischer M, LaPlante K, Allegretti J, Hasson BR, Fonte AT, McChalicher C, Ege DS, et al. SER-109: An Oral Investigational Microbiome Therapeutic for Patients with Recurrent Clostridioides difficile Infection (rCDI). Antibiotics. 2022; 11(9):1234. https://doi.org/10.3390/antibiotics11091234

Khanna, Sahil, Matthew Sims, Thomas J. Louie, Monika Fischer, Kerry LaPlante, Jessica Allegretti, Brooke R. Hasson, Allyson T. Fonte, Christopher McChalicher, David S. Ege, and et al. 2022. "SER-109: An Oral Investigational Microbiome Therapeutic for Patients with Recurrent Clostridioides difficile Infection (rCDI)" Antibiotics 11, no. 9: 1234. https://doi.org/10.3390/antibiotics11091234

Khanna, S., Sims, M., Louie, T. J., Fischer, M., LaPlante, K., Allegretti, J., Hasson, B. R., Fonte, A. T., McChalicher, C., Ege, D. S., Bryant, J. A., Straub, T. J., Ford, C. B., Henn, M. R., Wang, E. E. L., von Moltke, L., & Wilcox, M. H. (2022). SER-109: An Oral Investigational Microbiome Therapeutic for Patients with Recurrent Clostridioides difficile Infection (rCDI). Antibiotics, 11(9), 1234. https://doi.org/10.3390/antibiotics11091234